NeuroMetrix maintains an active R&D program. Our strategy is to develop unique, proprietary medical devices that utilize non-invasive neurostimulation to diagnose and treat neurological conditions and pain. We seek to define new product categories and leapfrog existing technology. We develop products using our specialized in-house 10-person R&D team.

Diagnostics

• DPNCheck^® 2.0 launched in Q3 2022

• DPNCheck^® Cloud under development

• Enhanced EHR integration

Therapeutics

The Quell^® technology currently has the following indications:

• reduction of chronic lower extremity pain (over-the-counter)*

• as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity (prescription)

We are seeking to expand the FDA authorized clinical indications to include a number of chronic pain and neurological conditions with high prevalence and unmet treatment needs.